期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
局部枸橼酸抗凝并连续性肾脏替代治疗患者体内钙离子水平稳定性管理的研究 被引量:1
1
作者 戴珍娟 徐沈婷 +4 位作者 周剑英 陈建勤 薛方英 王学敏 孙诗凡 《中华急危重症护理杂志》 CSCD 2024年第2期159-164,共6页
目的 探讨软件因素-硬件因素-环境因素-当事人及他人因素(software hardware environment liveware,SHEL)管理模式在局部枸橼酸抗凝(regional citrate anticoagulation,RCA)并连续性肾脏替代治疗(continuous renal replacement therapy,... 目的 探讨软件因素-硬件因素-环境因素-当事人及他人因素(software hardware environment liveware,SHEL)管理模式在局部枸橼酸抗凝(regional citrate anticoagulation,RCA)并连续性肾脏替代治疗(continuous renal replacement therapy,CRRT)患者钙离子水平稳定性管理中的应用效果。方法 通过前期基线调查,应用SHEL管理模式对钙离子和枸橼酸需要量数字模型实施中钙离子管理进行原因分析、对策拟定、过程控制并评价效果。采用便利抽样法,选取重症监护室2022年7月-12月行RCA-CRRT的84例患者为试验组,2022年1月-6月行RCA-CRRT的84例患者为对照组,比较两组治疗后体内血iCa^(2+)水平、桡动脉导管取样点准确率、单独静脉通道补钙途径正确率、钙和枸橼酸参数调整及时率、非计划性下机率、专科护士满意度的差异。结果 试验组治疗后2 h、4 h、8 h、12 h体内血iCa^(2+)水平差异无统计学意义(P=0.534),对照组治疗后2 h、4 h、8 h、12 h体内血iCa^(2+)水平有统计学差异(P=0.001);试验组非计划性下机率为9.5%,低于对照组10.7%,差异无统计学意义(P=0.798)。试验组桡动脉导管取样点正确率为97.6%,高于对照组81.0%;单独静脉通道补钙途径正确率为96.4%,高于对照组86.9%;钙和枸橼酸参数调整及时率为95.2%,高于对照组72.6%,差异均具有统计学意义(P<0.05)。护士满意度较对照组提高15.03%,对SHEL管理模式在RCA-CRRT治疗中钙管理的作用均给予肯定(P<0.001)。结论 采用SHEL管理模式能改善RCA-CRRT中的钙离子稳定性,提高专科护士满意度。 展开更多
关键词 连续性肾脏替代疗法 局部枸橼酸抗凝 软件因素-硬件因素-环境因素-当事人及他人因素管理模式 危重病护理
下载PDF
谨防领导“脱轨”
2
作者 田效勋 《企业管理》 2022年第8期29-32,共4页
领导“脱轨”导致的决策失败,会把组织拖入泥潭,甚至让企业陷入破产境地。领导也会“脱轨”原本有前途的领导,随着时间推移,逐渐出现偏离有效领导的行为,如不听正确的谏言导致战略冒进的决策失误、对明显正确的主张不勇于坚持等,这就是... 领导“脱轨”导致的决策失败,会把组织拖入泥潭,甚至让企业陷入破产境地。领导也会“脱轨”原本有前途的领导,随着时间推移,逐渐出现偏离有效领导的行为,如不听正确的谏言导致战略冒进的决策失误、对明显正确的主张不勇于坚持等,这就是领导“脱轨”。在人事决策时,重点评估的往往是候选人是否具备成功所需要的正向特征,对负向特征较少关注。 展开更多
关键词 领导“脱轨” 鸡蛋模型 个人因素 他人因素 环境因素 预防方法
下载PDF
Treatment of dyslipidemia in the elderly 被引量:1
3
作者 Hong Shao Li-Quan Chen Jun Xu 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2011年第1期55-64,共10页
Dyshpidemia is a well-established risk factor for atherosclerosis. Treating dyslipidemia in elderly patients requires specific knowledge and understanding of common dyslipidemias and the relative safety of various pha... Dyshpidemia is a well-established risk factor for atherosclerosis. Treating dyslipidemia in elderly patients requires specific knowledge and understanding of common dyslipidemias and the relative safety of various pharmacologic agents in the presence of possible multiple comorbidities. Lifestyle modification remains the first step in the treatment of dyslipidemia; however, it can be difficult to sustain and achieve acceptable compliance in the elderly and it is best used in combination with drug therapy. Statins are widely accepted as the first-line therapy. Several recent studies have demonstrated that statins are safe and effective in the elderly. However, it is important to note that there is very limited data regarding the effects of dyslipidemia treatment on morbidity and mortality in patients over 85 years of age. In summary, the clinicians must recognize that the presence of dyslipidemia in the elderly poses substantial risk of coronary events and stroke. The available evidence has demonstrated that in most elderly patients who are at increased risk for cardiovascular morbidity and mortality, treatment of dyslipidemia with appropriate therapy reduces the risk, and when used carefully with close monitoring for safety, the treatment is generally well tolerated. With increasing life expectancy, it is critical for physicians to recognize the importance of detection and treatment of dyslipidemia in the elderly. 展开更多
关键词 DYSLIPIDEMIA ATHEROSCLEROSIS STATINS
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部